RUNX2 and cancer: Ingenuity pathway analysis revealed that differentially methylated CpG sites were annotated to genes involved in ‘cancer’ (e.g. WT1, BCL2, BIN1, GATA6, RUNX2, EGFR) and ‘embryonic development’ (e.g. WT1, BMP4, FOXC1, GATA4), ‘cell death and survival’ (e.g. BCL2, EGFR, BMP4) ‘hematopoiesis’ (e.g. BMP4), ‘cell cycle’ (e.g. EGFR, BMP4), and ‘hematological diseases’(e.g. JAK2) (Figure S2A).